PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 2.92M (Avg.)
-0.48 | -4.19
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
1.01%
Revenue growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 0.36%. Joel Greenblatt would investigate if growth quality matches quantity.
51.22%
Cost growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 1.30%. Jim Chanos would check for structural cost disadvantages.
-129.16%
Gross profit decline while Drug Manufacturers - Specialty & Generic median is 0.81%. Seth Klarman would investigate competitive position.
-128.87%
Margin decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate competitive position.
3.64%
R&D change of 3.64% versus flat Drug Manufacturers - Specialty & Generic spending. Walter Schloss would verify adequacy.
-6.41%
G&A reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate efficiency gains.
-24.16%
Marketing expense reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate competitive implications.
-1.99%
Other expenses reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate advantages.
-8.97%
Operating expenses reduction while Drug Manufacturers - Specialty & Generic median is -1.41%. Seth Klarman would investigate advantages.
24.32%
Total costs growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 1.02%. Jim Chanos would check for waste.
-66.53%
Interest expense reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate advantages.
1.35%
D&A growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 0.36%. Jim Chanos would check for overinvestment.
-2230.01%
EBITDA decline while Drug Manufacturers - Specialty & Generic median is 1.49%. Seth Klarman would investigate causes.
-37.31%
EBITDA margin decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate causes.
-2648.08%
Operating income decline while Drug Manufacturers - Specialty & Generic median is 6.07%. Seth Klarman would investigate causes.
-2620.65%
Operating margin decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate causes.
100.80%
Other expenses growth while Drug Manufacturers - Specialty & Generic reduces costs. Peter Lynch would examine differences.
-1544.98%
Pre-tax income decline while Drug Manufacturers - Specialty & Generic median is 1.67%. Seth Klarman would investigate causes.
-1528.57%
Pre-tax margin decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate causes.
7.70%
Tax expense change of 7.70% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify strategy.
-1840.05%
Net income decline while Drug Manufacturers - Specialty & Generic median is 4.58%. Seth Klarman would investigate causes.
-1820.69%
Net margin decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate causes.
-1840.00%
EPS decline while Drug Manufacturers - Specialty & Generic median is 8.20%. Seth Klarman would investigate causes.
-1840.00%
Diluted EPS decline while Drug Manufacturers - Specialty & Generic median is 7.74%. Seth Klarman would investigate causes.
0.63%
Share count reduction below 50% of Drug Manufacturers - Specialty & Generic median of 0.08%. Jim Chanos would check for issues.
0.63%
Diluted share reduction below 50% of Drug Manufacturers - Specialty & Generic median of 0.04%. Jim Chanos would check for issues.